Implementation of Substance Use Treatment in Ambulatory Care

Provides guidance to physicians and pharmacists on buprenorphine regulatory requirements, prescribing, dispensing, and safety recommendations and additional information to improve decision making and promote beneficial outcomes.

Includes information for healthcare professionals, professional and patient organizations, and community groups, including tips for getting started, fact sheets on the requirements for providing chronic care management in practices, and educational materials to share with patients.

Provides tips and advice about commonly used CPT codes for buprenorphine treatment; how to set up a cash-only buprenorphine treatment program; Medicaid, Medicare, and private insurance coverage for buprenorphine treatment; and cost of buprenorphine treatment to patients.

Provides an overview of the current prior authorization landscape, including the status of electronic prior authorization adoption; the toolkit also looks ahead to the future of prior authorization and industry efforts and changes that will create a more efficient process.

Provides clinical tips and advice about basic induction and dosing, complications of induction, transfer of patients from methadone to buprenorphine, maintenance dosage, tapering/discontinuation, and medically supervised withdrawal (detoxification).

Provides lessons learned from organizations with established MAT programs, including making the business case for MAT, securing buy-in from staff, overcoming community resistance, paying for MAT, finding prescribers, obtaining licenses and credentials, screening and assessing patients, combining medication and therapy, and sustaining a MAT program.

Advises how providers obtain a waiver to prescribe buprenorphine; establish relationships with mental health professionals, laboratories, and pharmacies; and locate experienced buprenorphine prescribers for consultation. Describes staff responsibilities during induction and guidelines for prescriptions and medication refills.

Focuses on the unique realities of adolescent substance use, which includes abuse of illicit and prescription drugs, alcohol, and tobacco, and the special treatment needs of youths ages 12 to 17.

Guides users on how to navigate the process of connecting an electronic health record (EHR) to PDMP data through five steps: environmental scan, connection models, project plan, training and implementation, and evaluation and optimization.

Guides States, Tribes, and local communities on best practices for collaborative treatment approaches for women with SUDs. Highlights data on the effects of opioids on pregnant women and the risks and benefits associated with MAT.